Module 1 2021

28/06/2021

Presentation Outline

Introduction to Japanese Market

PMDA Scientific Advice

Clinical Trials in Japan vs Europe

Recent Updates & Regulatory Pathways

Cultural Considerations

Distribution to third parties is not allowed

3

Attractiveness of Japan for Drug Development

- Strong Economy (world number 3)

- Increasing Elderly population

- World-class reimbursement system

- Advanced Infrastructure for Clinical trials

- Highly Qualified work-force

Distribution to third parties is not allowed

4

2